EUVIMEDEUVIMED entdecken
Crossref

NAMPT Is A Novel Inhibitor of Vascular Calcification in Chronic Kidney Disease

Qianqian Dong, Lihe Lu iD, Xiuli Zhang iD, Liyun Feng iD, Li Li iD, Hao Liu, An Chen iD, Zirong Lan iD, Yuanzhi Ye iD, Jiahui Zhu iD, Xiaoyu Liu iD, Yining Li iD und 2 weitere

Arteriosclerosis, Thrombosis, and Vascular Biology · 2025

DOI: 10.1161/atvbaha.125.322549 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2025. Verfasst von Qianqian Dong und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Laboratory of Heart Center, Heart Center, Zhujiang Hospital (Q.D., X.Z., L.F., A.C., Z.L., Y.Y., J.Z., X.L., Y.L., J.Y.), S…. Hauptthemen laut MEDLINE: Nicotinamide Phosphoribosyltransferase, Vascular Calcification, Renal Insufficiency, Chronic, Cytokines. Die Arbeit nennt 74 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Vascular calcification is very common in patients with chronic kidney disease and contributes to the increased risk of cardiovascular events. NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the salvage pathway of nicotinamide adenine dinucleotide, has been shown to exert an antiaging effect on vascular smooth muscle cells. However, whether NAMPT is involved in the regulation of vascular calcification remains unclear. METHODS: ELISA, immunofluorescence, and Western blot were used to detect NAMPT levels in human blood and tissues. Alizarin red staining, calcium content assay, and microcomputed tomography were used to investigate the role of NAMPT in vascular calcification. Gene expression analysis and coimmunoprecipitation were performed to elucidate the underlying mechanism. RESULTS: ELISA, immunofluorescence, and Western blot showed that NAMPT levels were increased in the blood of patients with chronic kidney disease and human calcified arterial tissues. Alizarin red staining and calcium content assay revealed that pharmacological inhibition or knockdown of NAMPT exacerbated vascular smooth muscle cell calcification, whereas overexpression of NAMPT reduced mineral deposition under osteogenic conditions. Similarly, ex vivo studies revealed that NAMPT inhibited calcification of rat and human arterial rings. Moreover, administration of NAMPT inhibitor FK866 promoted aortic calcification of chronic kidney disease rats, and smooth muscle cell–specific NAMPT knockout mice exhibited aggravated aortic calcification. Furthermore, pharmacological inhibition and knockdown of SIRT1 (sirtuin 1) abrogated the inhibitory effect of NAMPT on vascular calcification. In addition, smooth muscle cell–specific SIRT1 deficiency abrogated the protective effect of recombinant NAMPT on mouse aortic calcification. Coimmunoprecipitation and immunofluorescence assay further revealed that NAMPT inhibited the acetylation of NICD (Notch intracellular domain) and reduced the expression of HES1 (hairy and enhancer of split-1) in a SIRT1-dependent pathway. CONCLUSIONS: Our study unveils that NAMPT could serve as a novel endogenous inhibitor of vascular calcification via modulation of SIRT1-mediated deacetylation of NICD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nicotinamide PhosphoribosyltransferaseVascular CalcificationRenal Insufficiency, ChronicCytokinesMuscle, Smooth, VascularMyocytes, Smooth MuscleAnimalsHumansSirtuin 1MaleCells, CulturedDisease Models, AnimalMice, Inbred C57BLMice, KnockoutSignal TransductionRatsMiceFemaleMiddle Aged

Stichwörter der Autor:innen

myocytes, smooth musclenicotinamide phosphoribosyltransferaserenal insufficiency, chronicsirtuin-1vascular calcification

Substanzen

Nicotinamide PhosphoribosyltransferaseCytokinesnicotinamide phosphoribosyltransferase, humanSirtuin 1nicotinamide phosphoribosyltransferase, mouseSIRT1 protein, humanSirt1 protein, mousenicotinamide phosphoribosyltransferase, rat

Autor:innen und Institutionen

  • Department of Cardiology, Laboratory of Heart Center, Heart Center, Zhujiang Hospital (Q.D., X.Z., L.F., A.C., Z.L., Y.Y., J.Z., X.L., Y.L., J.Y.), Southern Medical University, China.
  • Guangdong Provincial Key Laboratory of Cardiac Function and Microcirculation, Guangdong Provincial Biomedical Engineering Technology Research Center for Cardiovascular Disease, China (Q.D., X.Z., L.F., A.C., Z.L., Y.Y.,…
  • Department of Pathophysiology, Zhongshan Medical School, Sun Yat-Sen University, China (L. Lu).
  • Department of Cardiology, Guangzhou Red Cross Hospital, Jinan University, China (L. Li).
  • Division of Vascular and Interventional Radiology, Department of General Surgery, Nanfang Hospital (H.L.), Southern Medical University, China.
  • Department of Anesthesiology, The Third Affiliated Hospital (Q.L.), Southern Medical University, China.

ORCID-Profile: Lihe Lu, Xiuli Zhang, Liyun Feng, Li Li, An Chen, Zirong Lan, Yuanzhi Ye, Jiahui Zhu, Xiaoyu Liu, Yining Li, Qingchun Liang, Jianyun Yan

Zitieren

APA

Dong, Q., Lu, L., Zhang, X., Feng, L., Li, L., Liu, H., Chen, A., Lan, Z., Ye, Y., Zhu, J., Liu, X., Li, Y., Liang, Q., & Yan, J. (2025). NAMPT Is A Novel Inhibitor of Vascular Calcification in Chronic Kidney Disease. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.125.322549

Vancouver

Dong Q, Lu L, Zhang X, Feng L, Li L, Liu H, et al. NAMPT Is A Novel Inhibitor of Vascular Calcification in Chronic Kidney Disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2025. doi:10.1161/atvbaha.125.322549

BibTeX
@article{Dong2025,
  author = {Dong, Qianqian and Lu, Lihe and Zhang, Xiuli and Feng, Liyun and Li, Li and Liu, Hao and Chen, An and Lan, Zirong and Ye, Yuanzhi and Zhu, Jiahui and Liu, Xiaoyu and Li, Yining and Liang, Qingchun and Yan, Jianyun},
  title = {NAMPT Is A Novel Inhibitor of Vascular Calcification in Chronic Kidney Disease},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2025},
  doi = {10.1161/atvbaha.125.322549}
}
Kostenlos starten →